A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Clinical trial NCT03565406 · TERMINATED
Trial details
- NCT number
- NCT03565406
- Sponsor
- NYU Langone Health
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-25
- Primary completion
- 2020-01-13
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.